FSD Pharma and SCICANN Therapeutics launch clinical research program in Israel
FSD Pharma Inc. recently announced the launch of a clinical research collaborative program in Israel, via its strategic R&D partner, SciCann Therapeutics Inc.
FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
TORONTO, Aug. 23, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) reports today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), has achieved positive results in a pre-clinical efficacy study of its proprietary “Steady Stomach” CBD combination product for Inflammatory Bowel Disease (IBD). Under the terms of the agreement between FSD and SciCann, FSD Pharma holds exclusive marketing and distribution rights for the “Steady Stomach” product in Canada.
Khiron Announces Pricing of Marketed Short Form Prospectus Offering of Common Shares
TORONTO, Aug. 23, 2018 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company“) (TSXV: KHRN , OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to report that it has priced and sized its previously announced marketed offering of common shares at a price of $0.90 per share to raise aggregate gross proceeds of up to $11,250,000 (the “Offering“).
Gratomic: Perpetuus Concludes Successful Trials of Graphene-enhanced Tires – With an Average Increase of 40% in Wear Resistance
August 22, 2018 (Source) — UK-based Perpetuus Advanced Materials announced the completion of a “real world” road testing program of car tires enhanced with surface-engineered graphene materials.
FSD Pharma Completes Harvest and Microbial Testing of First Lot
TORONTO, Aug. 21, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.
Enforcer Gold terminates option agreement on the Montalembert Gold Property
TORONTO, Aug. 17, 2018 /CNW/ – Enforcer Gold Corp (“Enforcer” or the “Company”) (TSXV: VEIN) (FSE: N071) announces that it has determined not to proceed with its option to acquire a 100% interest in the Montalembert Property located in Quebec. Pursuant to the Option Agreement dated November 16, 2016, Enforcer has provided ninety (90) days written notice to Globex Mining Enterprises Inc. (“Globex”) (TSX: GMX) to terminate the option, effective November 15, 2018.
Enforcer Gold terminates option agreement on the Montalembert Gold Property
TORONTO, Aug. 17, 2018 /CNW/ – Enforcer Gold Corp (“Enforcer” or the “Company”) (TSXV: VEIN) (FSE: N071) announces that it has determined not to proceed with its option to acquire a 100% interest in the Montalembert Property located in Quebec. Pursuant to the Option Agreement dated November 16, 2016, Enforcer has provided ninety (90) days written notice to Globex Mining Enterprises Inc. (“Globex”) (TSX: GMX) to terminate the option, effective November 15, 2018.
Khiron lists on OTCQB Venture Market
TORONTO, Aug. 15, 2018 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company“) (TSXV: KHRN) (OTCQB: KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that the Company has successfully applied and been accepted for listing to the OTCQB Venture Market stock platform. The common shares of the Company will trade under the ticker symbol KHRNF.
FSD Pharma Announces Listing on Frankfurt Stock Exchange
TORONTO, Aug. 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares are now listed on the Frankfurt Stock Exchange (“FRA”) and are trading under the “WKN: A2JM6M” and the ticker symbol “0K9.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the OTC in the US under the ticker symbol “FSDDF.”
Gratomic Provides Update on Perpetuus Graphene Development Program
TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) — Gratomic Inc. (“GRAT” or the “Company”) (TSX-V:GRAT) (FRANKFURT:CB81, WKN:A2JAP3).